Lantern Pharma's Starlight Therapeutics Receives FDA Clearance for GBM Combination Trial

Lantern Pharma (NASDAQ: LTRN) has announced a significant milestone in the fight against glioblastoma multiforme (GBM), with its wholly owned subsidiary, Starlight Therapeutics, receiving FDA clearance to initiate a Phase Ib/2a clinical trial. The trial will evaluate STAR-001 (LP-184) in combination with spironolactone for patients with GBM at first progression, focusing on safety, tolerability, and preliminary efficacy. GBM is a highly aggressive form of brain cancer with limited treatment options, making this development a potential game-changer for patients and the oncology field.

STAR-001 is a brain-penetrant DNA-damaging agent designed to target DNA repair deficiencies through synthetic lethality, with its effectiveness enhanced by spironolactone, which induces NER deficiency in tumor cells. This innovative approach has garnered Orphan Drug and Fast Track designations from the FDA, underscoring its potential to address unmet medical needs in GBM treatment. The clinical program leverages Lantern Pharma's AI-driven RADR(R) platform to identify optimal patient populations and accelerate development timelines, showcasing the transformative power of AI in oncology drug development.

The clearance of this IND application builds on promising data from an ongoing Phase 1a trial, highlighting the therapeutic potential of STAR-001 in combination with spironolactone. For more details on the trial and Lantern Pharma's pioneering work in oncology, visit https://ibn.fm/8ndAq. This development not only represents a hopeful advance for GBM patients but also exemplifies the critical role of AI and innovative research methodologies in accelerating the discovery and development of life-saving cancer therapies.